Orion Nutraceuticals Adds Shannon Ford-Smith, Sports Healthcare and CBD Product Expert, to Advisory Board
November 20 2018 - 08:00AM
via NEWMEDIAWIRE --
Orion Nutraceuticals Inc.,
(CSE:
ORI) (the “
Company” or
“
Orion”) a cannabis life science company, is
pleased to announce the addition of Shannon Ford-Smith, sports
healthcare and CBD product expert to its advisory board.
Shannon Ford-Smith has a uniquely diverse background that
includes education, construction, consumer goods as well as
experience building and leading companies in the sports healthcare
sector. She has over a decade of experience building, leading and
establishing business direction.
Throughout her career she has developed deep market insight into
the healthcare field. Her recent executive role at Floydʼs of
Leadville as Director of Business Development includes the
development of Aeliza (a medical grade CBD product line) and
oversight of the Companyʼs expansion and growth into the Canadian
market, hiring and leading the execution of a common vision of
success while mitigating risk. She spearheaded development of the
Aeliza line and personally oversaw every detail, from product
development and formulation, manufacturing, business development,
marketing, strategy, as well as bridging the gap between the
medical world and cannabis.
“We are extremely pleased to add Shannon Ford-Smith to Orion
Nutraceuticals’ advisory board,” said Jonathan Fiteni, CEO of
Orion. “Her impressive resume includes a strong background in both
healthcare and business development. Shannon’s experience in
creating the CBD product line Aeliza will prove instrumental in the
creation of Orion’s own sports medicine CBD product lines.”
Ms. Ford-Smith started her career in healthcare with a focus
within the orthopaedic and sports rehabilitation industry. She
owned and operated Perpetual Motion, three multidisciplinary sports
rehabilitation clinics in Toronto. Her passion for helping people
fueled her desire to grow her brand of clinics. Her clientele
included top tier athletes, professional sports teams as well as
leading hospitals within the GTA.
Recognized as the youngest educator at The Canadian College of
Massage and Hydrotherapy as well as Sutherland-Chan Massage School
and Teaching Clinic, Shannon taught courses and led large teams of
students in the school student clinic.
Ms. Ford-Smith’s experience includes several years as a business
development consultant to many small and mid-size corporations. She
worked with executive teams to develop and implement business
strategies and identify and open new revenue streams. Creative and
abstract problem solving has long been Shannon’s strengths she uses
to help companies meet their goals and see new opportunities.
“It is an honour to be joining the advisory board
of Orion Nutraceuticals,” said Shannon Ford-Smith. “I am excited to
share my purpose and passion with an organization that has the same
drive for positive change in cannabis and health.”
Grant of Options
The Company also wishes to announce that it has granted
incentive stock options to of the Company to Shannon Ford-Smith for
the right to purchase up to an aggregate of 150,000 common shares
of the Company, exercisable at the price of $0.43 per share for two
years. The effective date of the grant of option is November 20,
2018. The stock options granted will be in accordance with the
Company’s Stock Option Plan and will have the required four months
hold period legend, pursuant to the Policies of the CSE and
regulatory authorities.
About Orion Nutraceuticals
Inc.
Orion Nutraceuticals Inc. aims to set a new standard in cannabis
life science by producing and developing innovative products with
key strategic partners in the industry. In conjunction with
its professional sports strategic alliances, the company is poised
to advance research and development in the plant science sector,
deliver science-based products and services, and market CBD
therapies to the mainstream with proprietary brands and
products. Medic-Oasis, Orion's subsidiary, has submitted
its application for an ACMPR license and is currently under review
with Health Canada. Build out is expected to begin in Q1 2019, with
completion of the 30,000 square foot facility expected by Q3 2019.
Orion Nutraceuticals is partners with Colombian based medical
cannabis corporation FCM Global. FCM supplies pharmaceutical,
nutritional, wellness, and cosmetic companies in legal markets
worldwide with customized medical cannabis extracts, oils, and
isolates at commercial scale. Orion shares trade in Canada on the
CSE under the symbol ORI.
ON BEHALF OF THE BOARD
Jonathan Fiteni, CEO
Orion Nutraceuticals Inc.
www.orionnutra.ca
Investor Relations
Robin Linden, Director
1.604.313.2768
investors@orionnutra.ca
Keep up to date with Orion on our social media
channels:
Twitter: @orionnutra
Facebook: @orionnutra
Instagram: @orionnutra
LinkedIn: @orionnutra
This news release may contain forward-looking
statements based on assumptions and judgments of management
regarding future events or results. Such statements are subject to
a variety of risks and uncertainties which could cause actual
events or results to differ materially from those reflected in the
forward-looking statements. The company disclaims any intention or
obligation to revise or update such statements. For a description
of the risks and uncertainties facing the Company and its business
and affairs, readers should refer to the Company’s Management’s
Discussion and Analysis and other disclosure filings with Canadian
securities regulators, which are posted on www.sedar.com.
This news release does not constitute an offer to
sell or solicitation of an offer to buy any of the securities
described herein and accordingly undue reliance should not be put
on such. Neither the Canadian Securities Exchange (CSE or CNSX
Markets), nor its Regulation Services Provider (as that term is
defined in policies of the CSE), accepts responsibility for the
adequacy or accuracy of this release. This news release does not
constitute an offer to sell or a solicitation of an offer to buy
any of the securities described herein in the United States. The
securities described herein have not been registered under the
United States Securities Act of 1933, as amended (the “U.S.
Securities Act”), or any state securities law and may not be
offered or sold in the “United States”, as such term is defined in
Regulation S promulgated under the U.S. Securities Act, unless
registered under the U.S. Securities Act and applicable state
securities laws or an exemption from such registration requirements
is available.
Old Republic (NYSE:ORI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Old Republic (NYSE:ORI)
Historical Stock Chart
From Mar 2023 to Mar 2024